Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The concurrent administration of adriamycin (intravenous) and verapamil (oral) is of considerable interest because of experimental data suggesting that resistance to adriamycin may be overcome by this means. The potential for a pharmacokinetic interaction between the two drugs has therefore been investigated in five patients with small cell lung cancer treated with combination chemotherapy comprising adriamycin, VP16, vincristine and cyclophosphamide. The data indicate that a significant interaction takes place. Adriamycin peak levels, terminal half-life and the volume of distribution at steady state are higher, whereas plasma drug clearance and the volume of the central compartment are lower with co-administration of verapamil. There was no evidence of enhanced drug toxicity in this study; however, the data should be considered in the interpretation of clinical trials in which adriamycin and verapamil are used together, both in terms of toxicity and tumour response.

Original publication

DOI

10.1007/bf00273394

Type

Journal article

Journal

Cancer Chemother Pharmacol

Publication Date

1986

Volume

18

Pages

239 - 242

Keywords

Administration, Oral, Carcinoma, Small Cell, Clinical Trials as Topic, Doxorubicin, Drug Interactions, Drug Therapy, Combination, Female, Half-Life, Humans, Injections, Intravenous, Kinetics, Lung Neoplasms, Male, Middle Aged, Random Allocation, Time Factors, Verapamil